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VaccineVaccines for foot-and-mouth disease (FMD) generally use oil adjuvants. For better immunization and
safety, an adjuvant should be selected only after careful consideration. In this study, we produced vacci-
nes for O, A, and Asia1 serotypes by mixing oil adjuvants, Emulsigen-D (ED), ISA 201, and ISA 206 with
and without an aluminum hydroxide (AL) gel and measured their immunogenicity and safety to obtain
information regarding critical differences (survival or weight loss) of vaccine quality in mice; the goal
of this test was to overcome the difficulties associated with experiments large or medium-sized animals.
The groups immunized with the vaccines containing only the oil adjuvants (ED, ISA 201, and ISA 206) had
similar or higher levels of neutralizing antibodies and structural protein antibodies for the FMD virus
(FMDV) than the groups immunized with the vaccines including the oil adjuvants mixed with the gel.
However, in a challenge test using a mouse model, the protection rate showed the highest results in
ISA 201 and ISA 206 mixed with AL. The mice immunized with vaccines containing ED showed temporary
weight loss in the early postvaccination stages. Cell-mediated immunity was formed relatively strongly
in the group vaccinated with vaccines including ISA 201 and ISA 206. We proposed that combinations of
these adjuvants represent candidates for future FMD vaccines.
 2016 The Authors. Published by Elsevier Ltd. This is an openaccess article under the CCBY license (http://
creativecommons.org/licenses/by/4.0/).1. Introduction
Foot-and-mouth disease (FMD) is a viral infectious disease that
forms vesicles in the mouth and hooves of artiodactyls, such as
pigs, cattle, sheep, and goats, resulting in weight loss, reduced milk
production, and growth delays. The disease can be spread rapidly
not only by the excrement of infected animals, but also by contam-
inated feed, vehicles, and humans. Thus, the economic damage is
substantial once an outbreak occurs. Therefore, FMD is subject to
international regulations for the global trade of both livestock
and their products [1,2]. The administration of vaccines is a highly
effective method for preventing FMD. The selection of an appropri-
ate adjuvant is the most important factor in determining the effi-
cacy of these vaccines. To ensure a prompt and appropriate
response to outbreaks of FMD, we previously investigated theimmune response and protective effects to develop vaccines, with
the aim of identifying the vaccine with the best immunogenicity
and protection against the virus O/Andong/SKR/2010, which was
isolated during FMD outbreaks in Korea in 2010 and 2011 [3]. In
another study [3], we performed an experiment using ISA 201,
ISA 206, Carbigen, Emulsigen-D (ED), and an aluminum hydroxide
(Al(OH)3; AL), gel in order to select adjuvants for pigs and dairy
goats. The ED with AL gel resulted in stronger immunity and pro-
tective effects compared to ED only. Thus, it remains to be deter-
mined whether the oil-based adjuvants ISA 201 and ISA 206
mixed with the gel result in better immune responses.
In studies of vaccine developments for FMD, it is desirable that
the adjuvants are applied directly to susceptible target animals.
However, such experiments are time-consuming and costly in pigs
and cattle. It is difficult to obtain precise decisive data like mortal-
ity and body weight variation in dealing with large or medium-
sized animals because of subjective analysis of protection or safety.
Hence, to establish a prompt and accurate comparison of the newly
developed adjuvant using a mouse model, we measured the immu-
nity on each serotype using the vaccines containing O, A, or Asia1
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tries and examined the safety and protection capability of each
adjuvant. The results were compared with those of pigs, the target
animals.2. Materials and methods
2.1. Virus purification and inactivation
The FMD viruses O/Andong/SKR/2010 and Asia1/MOG/05 were
used for antigen preparation in a BHK21 cell line. For virus infec-
tion, the culture medium was replaced with serum-free Dulbecco’s
modified Eagle’s medium (Cellgro, USA), and the cell was inocu-
lated with the virus. After 1 h of incubation at 37 C in an atmo-
sphere of 5% CO2, the extracellular virus was removed. Twenty-
four hours after infection, the viruses were inactivated by
0.003 N of BEI for 24 h and concentrated with polyethylene glycol
6000 (81260; Sigma Aldrich, WI, USA). The virus was layered on
15–45% sucrose density gradients and centrifuged [4]. After ultra-
centrifugation, the bottom of the centrifuge tube was punctured,
and 1 ml fractions were collected. The presence of FMD viral parti-
cles and the FMD viral protein in a sample of each fraction were
tested with a lateral flow device (BioSignTM FMDV Ag, PBM, USA).
The concentrated and inactivated FMDV, A22 Iraq antigen for type
A supplied byMerial Co. Ltd (UK) was used to manufacture the vac-
cines for the immunity and safety tests.
2.2. Preparation of the vaccines
The concentrated O/Andong/SKR/2010, A22 Iraq and Asia1/
MOG/05 antigens were diluted with a Tris-NaCl buffer (with a
pH of 7.6) and then added to each adjuvant: Emulisgen-D (ED;
MVP Technologies, USA), MontanideTM ISA 201 VG (ISA 201; Seppic,
France), Montanide ISA 206 VG (ISA 206; Seppic, France), and
aluminum hydroxide gel (AL; Rehydragel HPA; General Chemical,
USA). The ratio of the adjuvant to the total volume was 20:80 for
ED and 50:50 for both ISA 201 and ISA 206 (volume [v]/v). In the
oil/gel adjuvant mixture, 10% of AL was added. The mixture was
stirred at 300 rpm for 10 min at 30 C in a water incubator to form
a water-in-oil-in-water blend. The stability of the vaccines was
tested using the dropping method [5]. To maintain the same
amount of antigen per dose of vaccine, the same amount of antigen
was prediluted to the same concentration before mixing it with the
adjuvant.
2.3. Immunization and FMDV challenge in the mice
In the first study, eight-week-old female BALB/c mice were
divided into seven test groups (n = 4 in each group), and a
nonvaccinated control (NVC) group (n = 2). The test groups were
as follows: Carbigen, ED, ED + AL, ISA 201, ISA 201 + AL, ISA 206,
and ISA 206 + AL. With the exception of the control group, all the
mice were inoculated intramuscularly with an experimental vac-
cine containing 1 lg of inactivated antigen (O/Andong/SKR/2010),
and they were inoculated once more with the same method seven
weeks later. The serum of each mouse was collected 0, 2, 4, 6, 7,
and 9 weeks after vaccination. Nine weeks after the first vaccina-
tion, all the mice were stimulated with 1 lg of purified virion anti-
gen (O/Andong/SKR/2010) for cell-mediated immune responses,
and cytokine assays were performed on blood samples collected
24 h after the stimulation.
In the second study, eight-week-old female C57BL/6 mice
(n = 3) were used to compare the seven vaccinated groups (ED,
ED + AL, ISA 201, ISA 201 + AL, ISA 206, ISA 206 + AL, and FMD
trivalent vaccine [Aftopor Trivalent, Merial, France]) and thenonvaccinated group. All the mice were vaccinated intramuscu-
larly with an experimental vaccine containing 1 lg of inactivated
antigen (A22 Iraq). On the 28th day after vaccination (dpv), all
the mice were challenged with 106.0 of TCID50/0.1 ml of A22 Iraq
by the intraperitoneal route. Sera were collected 0, 2, 4, and
6 weeks after vaccination and 3 days after the challenge, and
antibodies to the virus and the FMDV structural proteins (SPs)
were measured. For the safety test, the safety of the ED, ED + AL,
ISA 201, and ISA 201 + AL vaccines was tested in eight-week-old
female C57BL/6 mice. The FMDV trivalent vaccine was used as a
control. In the safety test, each group (n = 8) received a subcuta-
neous vaccination containing 50 ll of each adjuvant. Each mouse
was weighed daily for 10 days after vaccination.
In the third study, eight-week-old female C57BL/6 mice were
divided into the seven groups (ED, ED + AL, ISA 201, ISA 20 + AL,
ISA 206, ISA 206 + AL, and FMD trivalent vaccine [Aftopor Triva-
lent, Merial, France]) (n = 8) and the nonvaccinated group (n = 4).
First, to observe early immune reaction, the mice were vaccinated
with 0.2 lg of inactivated antigen (Asia1/MOG/05) and challenged
with 100 median lethal dose (LD50) of Asia1/Sha/89 (Asia1 Shamir)
after one week fater vaccination. To observe mid-term immune
reaction, the challenge was performed in an identical manner four
weeks after vaccination. The survival rate was checked for 10 days
after the challenge. To investigate long-term immune reaction, the
mice were challenged 12 weeks after vaccination and were
observed for 10 days after the challenge.
2.4. Immunization and FMDV challenge in pigs
For the pig experiment, the pig serum employed in the previous
study was used [3]. The 22 female pigs (eight-week-old) were
divided into five test groups (n = 4 each group; Carbigen, ED, ISA
201, ISA 206, ED with AL [ED + AL]) and an unvaccinated control
group (n = 2). All the pigs were inoculated with an experimental
vaccine containing 10 lg of antigen per dose (2 ml). The serum of
the pigs was collected into serum-separating tubes 0, 7, 14, 21,
and 28 days after vaccination, and neutralizing antibodies were
measured. At 28 days after vaccination, test pigs were challenged
with 105.0TCID50/0.1 ml of FMDV O/Andong/SKR/2010 from the
vesicles of infected pigs by intradermally injecting it into the foot
pad. The sera collected one day after the challenge and 10 days
after the challenge were used to measure the SP antibodies for
the FMD virus and IL-12 and IL-4 cytokine secretion, respectively.
In the pig test, the sera of only the ED, ISA 201, and ISA 206 groups
were used after excluding the Carbigen and ED + AL.
2.5. Structural protein (SP) ELISA and nonstructural protein (NSP)
ELISA
For the detection of SP antibodies, PrioCHECK FMDV type A and
type O (Prionics AG, Schlieren-Zurich, Switzerland) were used.
Nonstructural protein (NSP) antibodies were detected with a
PrioCHECK FMDV NSP (Prionics AG, Schlieren-Zurich, Switzerland)
ELISA kit in serum samples of mice. The absorbance of the ELISA
plate was converted to the percent inhibition (PI) value. When
the PI was 50% or above, the mice were regarded as antibody
positive.
2.6. Virus neutralization test
Titers of neutralizing antibodies in the serum were measured
with a virus neutralization test. Serum samples were collected
from the animals after the vaccinations and the virus challenge.
The serum samples were heat inactivated at 56 C for 30 min.
Following incubation of the test serum with FMDV 100 TCID50/
0.1 ml for 1 h, LF-BK cells were added to the plate and incubated
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the titers that were calculated as the log10 of the reciprocal anti-
body dilution to neutralize 100 TCID50 of the virus [6].
2.7. Analysis of the replication of the FMDV in the mice
Real-time RT-PCR was performed for heparinized blood and
swab samples from the test animals. The swab samples were gath-
ered from the mouth and nose using cotton swabs. Total cellular
RNA was extracted using the MagNa pure 96 system (Roche, Ger-
many) according to the manufacturer’s protocol. Real-time RT-
PCR was conducted using the one-step Primescript RT-PCR kit
(TAKARA, Otsu, Japan). These procedures were conducted accord-
ing to the manufacturer’s instructions. Primers targeting the FMDV
3D region were sense 50-GGAACYGGGTTTTAYAAACCTGTRAT-30
and antisense 50-CCTCTCCTTTGCACGCCGTGGGA-30. The probe
was 50-CCCADCGCAGGTAAAGYGATCTGTA-30. Its 50 end was
labeled with 6-FAM, and the 30 end was labeled with TAMRA.
The CFX96 TouchTM Real-Time PCR Detection system (Bio-Rad,
USA) was used [7].
2.8. Determination of cell-mediated immunity
Th1 cytokine and Th2 cytokine secretion were identified with
Bio-Plex ProTM cytokine assays (Bio-Rad, USA). After the second
immunization with the vaccines, all mice were stimulated withBA
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Fig. 1. Immune responses in the mice vaccinated with the various adjuvants for the e
vaccinated with the experimental type O (O/Andong/SKR/2010) FMD vaccine mixed w
vaccination dose was 1/10 (1 dose = dose for one cow or pig). (A) Antibody titers of structu
14, 28, 42, 63, and 64 days postvaccination (dpv). All the mice were stimulated with 2 lg
positive reaction. (B) Serum-neutralizing antibody responses (log 10) to the various adjuv
represents the standard error of the means. (C) Th1 (IL-2, IL-12, GM-CSF, IFN-gamma, an
groups were identified. Black-filled rectangle: 14 days after the second vaccination. White
purified virion antigen (O/Andong/SKR/2010) of 1 lg/head. ⁄p < 0.05. The error bar reprethe inactivated antigen O/Andong/SKR/2010 (1 lg/mouse). One
day later, the secretion of Th1 (IL-2, IL-12, GM-CSF, and IFN-
gamma, and TNF-alpha) and Th2 cytokines (IL-4, IL-5, and IL-10)
was measured.
For the pig experiment, a porcine IL-4 ELISA kit (R&D Systems,
MN, USA) and a porcine IL-12/IL-23 p40 Quantikine ELISA kit
(R&D Systems, MN, USA) were used.
2.9. Statistical analysis
Student’s t-test was performed with GraphPad Instat v. 3.05
(GraphPad Software, CA, USA) to examine the immunogenicity
and protective effects of the vaccines.
3. Results
3.1. Immune responses after vaccination with oil or gel-mixed
adjuvants in mice
Seven weeks (49 days) after the first vaccination with the type
O antigen, boosting was performed with the same vaccines, and
changes in the antibody titers were observed until the ninth week
(64 days). High levels of antibodies after the first vaccination were
detected in the ED, ED + AL, and ISA 201 vaccination groups
(>1:100 of virus neutralizing [VN] titer) (Fig. 1A, B). The other vac-
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xperimental type O foot-and-mouth disease (FMD) vaccine. All BALB/c mice were
ith the various adjuvants and boosted 49 days later with the same vaccine. The
ral protein (SP) against the FMD virus (FMDV) in the serumwere measured by ELISA
of purified antigen 63 dpv. Percent inhibition (PI)>50 was considered the cutoff of a
anted FMD vaccines. NVC: nonvaccinated control. ⁄p < 0.05, ⁄⁄ p < 0.01. The error bar
d TNF-alpha) and Th2 (IL-4, IL-5, and IL-10) cytokines in the adjuvanted vaccination
-filled rectangle: 1 day after stimulation (15 days after the second vaccination) with
sents the standard error of the means.
100 M.-E. Park et al. / Trials in Vaccinology 5 (2016) 97–104antibodies (>1:100) only after the second vaccination (Fig. 1B). Six
weeks (42 days) after the first vaccination, ISA 201 exhibited the
highest potential for the production of neutralizing antibodies, fol-
lowed by ED + AL and ED. The ED and ISA 206 adjuvants mixed
with AL did not result in statistically significant increases com-
pared to unmixed oil adjuvants. The high level of neutralizing anti-
bodies in the ED + AL or ISA 201 groups exhibited a statistically
significant difference from that in the ISA206 group (p < 0.05). Nine
weeks (63 days) after the vaccination, the highest level of neutral-
izing antibodies was detected in the ED group. The neutralizing
antibodies of the ED, ISA 201, and ISA 206 groups exhibited no sta-
tistically significant differences from those of the AL-mixed groups
with AL (p > 0.05) (Fig. 1B).
In the analysis of cell-mediated immunity through Th1 (IL-12,
GM-CSF, and TNF-a) and Th2 (IL-5, and IL-10) cytokines within
the sera of mice stimulated with inactivated antigen after the sec-
ond vaccination, ISA 201 and ISA 206 groups exhibited the stron-
gest cytokine secretion (Fig. 1C).3.2. Safety and viremia after vaccination and challenge
To identify the protective effects and the safety of the adjuvants,
the type A (A22 Iraq) antigen was selected and used in a challenge
experiment with the various adjuvanted vaccines in the C57BL/6
mouse [8]. SP ELISA antibodies to the FMDV were detected in the
serum two weeks (14 dpv) and six weeks (42 days) after the first
vaccination (Fig. 2A). High levels of neutralizing antibodies were
detected in sera of the ED, ED + AL, and ISA 201 vaccination groups
two weeks (14 days) post vaccination. The level of decline in neu-
tralizing antibodies was lower in the ISA 201 + AL group than in theA
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Fig. 2. Protective profile and virulence in mice of the various adjuvants for the experim
against the FMDV in the serum were measured by ELISA 14 and 42 dpv. (B) Serum-neutra
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with the various adjuvants. All the C57BL/6 mice were vaccinated via the intraperitonea
with the A22 FMDV 28 dpv. Three days after the challenge, serum was collected, and viru
standard error of the means. Trivalent: trivalent vaccine (Merial), NVC: nonvaccinated c
performed and the values were expressed as ⁄p < 0.05, ⁄⁄p < 0.01, ⁄⁄⁄p < 0.001.ISA 201 group. It was also lower in the ISA 206 group than in the
ISA 201 and ED groups. Only a low level of neutralizing antibodies
was detected in the commercial trivalent vaccine vaccination
group (Fig. 2B).
Fig. 2C shows the body weight changes in mice resulting from
the ED and ISA 201 adjuvants mixed with AL inoculation, and all
tested mice were alive during the safety test. However, most of
the mice in the ED and ED + AL groups underwent weight loss until
the second day after vaccination but exhibited a pattern of recov-
ery from the fourth day after vaccination (Fig. 2C). The ISA 201
and ISA 201 + AL vaccination groups exhibited no pattern of weight
loss compared to the ED or ED + AL groups (p < 0.05 in the second
days after vaccination). The currently used commercial trivalent
vaccine was associated with about a 2% decline in weight until
the second days after vaccination. The body weight recovered from
the fourth day and increased gradually thereafter. Three days after
the virus challenge, low-titer viruses were detected only in the sera
of the groups inoculated with the trivalent vaccine and ED + AL
(Fig. 2D).3.3. Comparison of vaccination experiments in mice
When the results of many adjuvants in the first and second
experiments were compared (Table 1), the ED, ED + AL, and ISA
201 vaccination groups showed high levels of immunogenicity
(>1:100 of VN titer). The groups immunized with ED exhibited a
weight loss. In terms of cell-mediated immune responses, the ED
and ED + AL vaccination groups exhibited statistically significant
increases after antigen stimulation in both Th1 and Th2 cytokines,
although they exhibited a low level of cytokines. Th1 reactivity wasB
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Table 1
Summary of the protective effect of the various adjuvants and the immune responses after vaccination in mice.
Groups vaccinated
with the various
adjuvants
Vaccination twicea Vaccination onceb
Rate (%) of animals
with a high VN titerc
No. of cytokines of high level d (after 2nd
vac./after antigen stimul./total)
No. of cytokines showing a significant
changed (p < 0.05) after antigen stimul.
(reacted/total)
Rate (%) of animals
with a high VN titer
Rate (%) of animals
with viremia after
challenge
Rate(%) of animal
with body
weight loss
42dpvj 63dpv Th1e Th2f Th1e Th2f 14dpv 2dpv 7dpv
ED g 75 100 0/1/5 0/0/3 1/5 3/3 0 0 88 13
ED + ALh 50 100 0/2/5 0/0/3 3/5 2/3 33 33 100 25
ISA 201 75 100 1/3/5 0/1/3 1/5 0/3 33 0 13 0
ISA 201 + AL 0 75 1/1/5 0/0/3 1/5 0/3 0 0 25 25
ISA 206 0 100 3/3/5 0/0/3 1/5 0/3 0 0 n.d. n.d.
ISA 206 + AL 25 100 1/0/5 0/0/3 1/5 0/3 0 0 n.d. n.d.
Carbigen 0 0 0/0/5 0/0/3 1/5 0/3 n.d n.d n.d n.d
Trivalent vaccine n.d. k n.d. n.d. n.d. n.d. n.d. 0 67 63 0
NVC i 0.0 0.0 0/0/5 0/0/3 0/5 0/3 0 100 n.d n.d
a BALB/c mice vaccinated twice with the experimental O/Andong/SKR/2010 vaccine.
b C57BL/6 mice vaccinated once with the experimental A22 Iraq vaccine or commercial vaccine (types O, A, Asia1).
c A high virus neutralizing (VN) antibody titer was defined as a value of >1:100.
d A high level of cytokines in sera was defined as a value of >100 pg/ml.
e Th1 type includes five cytokines; IL-2, IL-12, GM-CSF, IFN-gamma, and TNF-alpha.
f Th2 type includes three cytokines; IL-4, IL-5, and IL-10.
g ED: Emulsigen-D.
h AL: aluminum hydroxide.
i NVC: nonvaccinated control.
j dpv: days postvaccination.
k n.d.: not done.
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Fig. 3. Variation of mouse survival after type Asia1 vaccination according to the various adjuvants and various challenge points. (A) Survival rate of C57BL/6 mice after
vaccination (7 dpv) and challenge with the various adjuvants. All the mice were vaccinated via the intramuscular route. One week after vaccination, all the mice were
challenged with 100 LD50 of Asia1 Shamir FMDV. (B) Survival rate of C57BL/6 mice after vaccination (28 dpv) and challenge with the various adjuvants. (C) Survival rate of
C57BL/6 mice after vaccination (84 dpv) and challenge with the various adjuvants. (D) Variation of survival rate according to different adjuvants and various challenge points.
102 M.-E. Park et al. / Trials in Vaccinology 5 (2016) 97–104stronger in the ED + AL vaccination group than the ED-only vacci-
nation group. The ISA 201 group had a high level (>100 pg/ml) of
IL-12, GM-CSF, and TNF-alpha both days on days 63 and 64 after
the second vaccination and antigen stimulation (Table 1 and
Fig. 1C).
In the safety test, 88% of the mice in the ED group exhibited
weight loss on the second day after vaccination. Although weight
loss was observed in all the mice in the ED + AL vaccination group,
on the seventh day after vaccination, the level of weight loss was
low in the ED and ED + AL vaccination groups (13% and 25%,
respectively). The weight loss in the ISA 201 and ISA 201 + AL vac-
cination groups was 13% and 25%, respectively on the second day
after vaccination. However, all the animals in the ISA 201 vaccina-
tion group showed weight loss recovery, whereas those in the ISA
201 + AL vaccination group did not, with the weight loss continu-
ing subsequent to the fourth day after vaccination (Table 1).3.4. Variation of mouse survival by various challenge times
To compare the protection ability after vaccination, the survival
rate was observed following a vaccination and challenge of Asia1
Shamir to a challenge model of C57BL/6 mice. First, an early immu-
nity reaction was observed during the first week after vaccination
(Fig. 3A). As shown in Fig. 3A, the ISA 206 + AL group had the stron-
gest protection and early protection (seven days after vaccination)
was also possible in the ISA 201 + AL group. The virus challenge
was performed four weeks after vaccination to observe the mid-
term immunity (28 days after vaccination), and the survival rate
improved overall compared to the short-term (seven days after
vaccination) group (Fig. 3B). In particular, all vaccinated mice sur-
vived in the case of ISA 206 + AL and ED + AL groups, and the ISA
201 + AL group showed the second highest survival rate. In thelong-term (84 days after vaccination) group (Fig. 3C), the survival
rate was highest in the ISA 201 + AL group, and second highest in
the ISA 206 + AL group. In the ISA201 + AL, and ISA206 + AL groups,
the survival rate was highly maintained until day 84 after vaccina-
tion (Fig. 3D).
3.5. Comparison with the immunity results in pigs
We tested the immunogenicity and cytokine secretion in pigs,
the target animals, when either ED, ISA 201, or ISA 206 was used
as the adjuvant. Fig. 4A shows the measurement of neutralizing
antibodies after vaccination and challenge. Whereas the highest
concentration of neutralizing antibodies was detected in the ED
group in the early stage (7 day postvaccination [dpv]), the highest
concentration was detected in the ISA 206 group 14dpv and in ISA
201 21dpv and 28dpv. The antibody against NSPs of FMDV in the
sera was measured ten days after the challenge. According to the
results, the lowest concentration of the NSP antibody was detected
in the ISA 201-adjuvanted vaccine group, indicating no replication
of virus in the animals. A similar level of the NSP antibody was
detected in the ED and ISA 206 groups (Fig. 4B). The Th1-type cyto-
kine of the IL-12 and the Th2-type cytokine of IL-4 were measured,
and a higher level of the Th1-type cytokine was detected in the ED
and ISA 201 groups (Fig. 4C). However, a similar level of the Th2-
type cytokine of similar level was detected in four groups (Fig. 4D).4. Discussion and conclusions
The selection of adjuvants in FMD vaccine formulation is impor-
tant for both early and long-lasting immunity and protection. We
previously investigated the immunogenicity and antigenicity of
vaccine adjuvants using pigs and dairy goats as target animals
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Fig. 4. Protective profile in pigs of the various adjuvants for the experimental type O FMD vaccine. (A) Neutralizing antibody titers in the sera by various experimental FMD
vaccines until four weeks after vaccination and 10 days postchallenge (dpc). Neutralizing antibody titers of >1:45 (1.653 log10) was considered the cutoff of protectable value.
(B) Antibodies against non-structural protein (NSP) of FMDV from challenged animals in the porcine sera were measured by NSP-ELISA 10 dpc, PI > 50 was considered the
cutoff of a positive reaction. (C) IL-12 cytokine secretion in porcine serum was detected 1 dpc. All the pigs were inoculated with an experimental vaccine containing 10 lg of
antigen per dose (2 ml). At 28 dpv, test pigs were challenged with FMDV O/Andong/SKR/2010, (D) IL-4 cytokine secretion in porcine serum was detected at 1 dpc. Student’s t-
test was performed and the values were expressed as ⁄p < 0.05.
M.-E. Park et al. / Trials in Vaccinology 5 (2016) 97–104 103for the FMD vaccine [3]. The Al(OH)3 gel (AL) is the most commonly
used adjuvant in commercial vaccines [15]. A previous report
showed that AL induces Th2-type responses in animal models,
facilitating the dissemination of antibodies from the injected
region [9,10]. In addition, the gel was shown to play an important
role in memory responses by inducing the differentiation of macro-
phages. Gel-adjuvanted FMD vaccines are currently used only in
cattle, because they offer only a short period of immunity, making
them unsuitable for use in pigs [11]. Moreover, the immune
responses in sheep and goats are poorer than those of oil-based
vaccines [12,13]. The combined components of oil and AL have
been used to protect against rabies in bovines [16]. However, the
components for FMD have not been studied. We confirmed that
vaccine’s stability, which means no separating as oil-layer and
water layer in the contents of experimental vaccine, had main-
tained for three months.
In a previous study [3], we tested a combination of oil with a gel
to enhance the immune responses. We found that the inoculation
with ED + AL produced superior effects in pigs or goats, target ani-
mals. We tentatively concluded that AL improves the effects of ED
adjuvants; in present study, we thus attempted to demonstrate
that mixing with various oil-adjuvant and gel would induces sim-
ilar protection in mice. We confirmed slight increases in the level
of humoral immune response in the ED + AL and ISA 206 + AL
groups and a reduced level of immunity in the ISA 201 + AL group.
Therefore, not all types of oil vaccines are likely to induce the same
immune reactions. We also examined the reactivity of the Th1/Th2
paradigm, which is a new indicator of immune response [14].
Although most of the vaccination groups showed Th1 reactivity
(IL-2 cytokine responses) after antigen stimulation following the
second vaccination, only the ED and ED + AL vaccination groupsexhibited statistically significant changes in Th2-type cytokine
responses. Furthermore, the ISA 201 and ISA 206 vaccination
groups showed a high level of Th1 and Th2 cytokines in the days
following the second vaccination or antigen stimulation. Through
the formation of strong immune responses for both Th1 and Th2
type, we confirmed the immune stimulation effects of the adju-
vants. The addition of AL did not induce a substantial change in
the formation of antibodies. Moreover, the associated weight loss
in the vaccination groups with the AL gel added to the
vaccination-related stress. According to the protection results
using the challenge model, ISA 201 + AL and ISA 206 + AL showed
the best performance in short-, mid-, and long-term immune reac-
tions. The protection rate of the oil vaccine was not high in the case
of oil-only use, but it improved remarkably when mixed with gel.
Th1-type cytokine in the pigs was relatively strongly detected in
the ED and ISA 201 groups, indicating a potential impact on protec-
tion ability. In NSP ELISA or virus neutralization antibody tests in
pigs, ISA 201 had the best results. Summarizing the evaluation
results on the immunity, safety, and protection of the test animal
and target animal, we suggest that ISA 201 and ISA 206 are effec-
tive. In the case of ED + AL, survival effects after the mid-term per-
iod (28 dpv) were observed. In a previous study, it was confirmed
that the mixed use of ED and gel can improve the protection ability
in the target animal [3]. However, no research has examined the
direct improving potential of the mixed use of ISA 201 or ISA206
and AL gel, and hence additional experiments in target animals is
necessary. The current findings differ slightly from those of our
previous experiment using pigs [3], in which increased immunity
was detected. Differences in the immunity and injected dose
according to species, small laboratory animals (mice) and target
animals (pigs), may explain the discordant findings.
104 M.-E. Park et al. / Trials in Vaccinology 5 (2016) 97–104In conclusion, this study showed increases in the protective
effects of adding AL to ED, ISA 206, and ISA201. In the case of ISA
201, this mixture produced reduced levels of humoral immunity.
However, ISA 201 and ISA201 + AL resulted in better cell-
mediated immune response and safety in mice. Weight loss was
observed for a short period after vaccination in the ED and ED
+ AL groups post vaccinations. Because this study used mice,
although the safety and weight loss can be expected to be different
in large and medium-sized animals susceptible to FMD when vac-
cinated in the field, prior to the application of ED, ISA 206 or ISA
201 with gel in the target animals in the field, the experiments
designed to determine its safety in the small laboratory animal
would be needed. Oil-adjuvanted vaccines can result in the forma-
tion of local lesions in the injected areas. Thus, to avoid granuloma,
long-term studies with a reduced volume of vaccines should be
carried out to identify whether such lesions increase or decrease
when AL gel is added to the vaccines. In addition, comparative
studies on long-lasting immunity in experimental and target ani-
mals may be required for the development of new vaccines.
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